XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma
Phase 2
Completed
- Conditions
- Eosinophilic AsthmaBronchial Asthma
- Interventions
- Drug: PlaceboDrug: XC8 100 mg
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Chemlmmune Therapeutics LLC
- Target Recruit Count
- 70
- Registration Number
- NCT04674137
- Locations
- 🇷🇺
JSC "Polyclinic complex", Saint Petersburg, Russian Federation
🇷🇺Saint Petersburg State Budgetary Institution of Healthcare St. Martyr Elizabeth City Hospital", Saint Petersburg, Russian Federation
🇷🇺LLS Research Center for Eco-Security, Saint Petersburg, Russian Federation
© Copyright 2025. All Rights Reserved by MedPath